Share

    


Home / Search Results

Search Results

You searched for:

In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
At the risk of repeating a phrase that has been exhausted this year, the dawn of 2020 brought with it unprecedented times. Whereas a pandemic on its own would have dominated everything else, this year also brought on an economic depression; a racial awakening; record-breaking wildfires, hurricanes, and floods; political turmoil on an extraordinary scale; and a host of additional unique phenomena. …
For resources on COVID-19 as it applies to the oncology community, please visit ACCC’s continually updated Coronavirus Resource page. ACCC members can also access ACCCExchange, a listserv that allows them to communicate in real time with their colleagues about how the COVID-19 virus is affecting their communities and their patients. As COVID-19 spreads across the U.S., not everyone will get sick. …
The topic of drug waste is nothing new in healthcare. Over the years, reports have surfaced attempting to put a dollar amount on this waste. In 2017, the Centers for Medicaid and Medicare Services began requiring all physicians, hospitals, and other providers submitting Medicare Part B drug claims to report any discarded amount of a single use vial or other single use package drug on its claim for …
As we turn the calendar page to a new year, we inevitably pause to take a quick look back. At ACCC, 2018 has been a year of forward-looking advances. Over the past 12 months, ACCC launched its newly designed website and brought the Association’s immuno-oncology initiative, now named the ACCC Immuno-Oncology Institute, to the next level. That's not all. In March, ACCC released its Financial Advocacy …